De novo mixed neuroendocrine prostate cancer: a case report and literature review

Background: Neuroendocrine prostate cancer (NEPC) represents a rare and highly aggressive subtype of prostate cancer that is prone to early metastatic progression. Currently, no standardized treatment protocol has been established for this disease, posing substantial challenges for its diagnosis and management. Case: This report provides a detailed account of the diagnostic and therapeutic course of an 82-year-old patient with de novo NEPC. The patient presented with a prostate mass identified on routine physical examination and was diagnosed with NEPC after comprehensive clinical work‑up. Multiple distant metastases developed six months after radical prostatectomy. Through multidisciplinary collaboration, a personalized therapeutic regimen was implemented, and the patient achieved a partial response. Conclusions: This case suggests that multimodal diagnostic approaches and comprehensive therapeutic strategies are clinically valuable in the management of NEPC and may provide a reference for future studies.

Neuroendocrine prostate cancer; Prostate cancer; Diagnosis; Treatment; Case report

[1] Lin X, Zhi Y. Global epidemiological trends in prostate cancer burden: a comprehensive analysis from Global Burden of Disease Study 2021. Translational Andrology and Urology. 2025; 14: 1238–1252.

[2] Vassilev Z, Said Q, Zong J, Khan N, Rentzsch C, Barel G, et al. Epidemiology and treatments of neuroendocrine prostate cancer in a large commercially insured population in the US. Cancer Treatment and Research Communications. 2025; 45: 101038.

[3] Taher A, Jensen CT, Yedururi S, Surasi DS, Faria SC, Bathala TK, et al. Imaging of neuroendocrine prostatic carcinoma. Cancers. 2021; 13: 5765.

[4] Cai M, Zheng F, Ren YZ, Zhen C, Fu D, Song XL, et al. New insights into potential therapeutic targets for neuroendocrine prostate cancer: from bench to clinic. Research. 2025; 8: 0791.

[5] Fernandes R, Dos Santos J, Reis F, Monteiro S. Cushing syndrome as a manifestation of neuroendocrine prostate cancer: a rare presentation within a rare tumor. Cureus. 2021; 13: e18160.

[6] Siech C, de Angelis M, Jannello LMI, Di Bello F, Rodriguez Peñaranda N, Goyal JA, et al. Rare histological prostate cancer subtypes: cancer-specific and other-cause mortality. Prostate Cancer and Prostatic Diseases. 2025; 28: 748–754.

[7] Apostolidis L, Nientiedt C, Winkler EC, Berger AK, Kratochwil C, Kaiser A, et al. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget. 2019; 10: 17–29.

[8] Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, et al. Morphologic, molecular and clinical features of aggressive variant prostate cancer. Cells. 2020; 9: 1073.

[9] Lobo A, Cheng L. Reappraisal of neuroendocrine tumor classification of the prostate gland: translating molecular insights into clinical practice. Endocrine Pathology. 2025; 36: 28.

[10] Albuquerque-Castro Â, Macedo-Silva C, Oliveira-Sousa R, Constâncio V, Lobo J, Carneiro I, et al. Redefining prostate cancer risk stratification: a pioneering strategy to estimate outcome based on Ki67 immunoscoring. Biomarker Research. 2024; 12: 75. Erratum in: Biomarker Research. 2024; 12: 121.

[11] Zhang B, Zhu Y, Huang R, Zhou F, Ling Z. Treatment-related pure large-cell neuroendocrine carcinoma of the prostate with systemic metastases in a young adult: a rare case report. Frontiers in Oncology. 2025; 15: 1617699.

[12] Zhang Y, Shi M, Zhang Y, Wang J, Zhang H, Ren G. RB1 and p53 are diagnostic markers for treatment-related neuroendocrine prostate cancer: a clinical and pathological analysis of 23 cases. American Journal of Clinical and Experimental Urology. 2025; 13: 118–131.

[13] Maylin ZR, Smith C, Classen A, Asim M, Pandha H, Wang Y. Therapeutic exploitation of neuroendocrine transdifferentiation drivers in prostate cancer. Cells. 2024; 13: 1999.

[14] Zhao SG, Sperger JM, Schehr JL, McKay RR, Emamekhoo H, Singh A, et al. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. The Journal of Clinical Investigation. 2022; 132: e161858.

[15] Han W, Rexiati N, Yu F, Wang Y, Tian Y, Wu J, et al. A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review. Frontiers in Oncology. 2025; 15: 1508410.

[16] Gravestock P, Somani BK, Tokas T, Rai BP. A review of modern imaging landscape for prostate cancer: a comprehensive clinical guide. Journal of Clinical Medicine. 2023; 12: 1186.

[17] Nixon B, Aher P. Neuroendocrine prostate cancer: report of a prostate cancer subtype with atypical metastatic imaging and clinical findings. Journal of Radiology Case Reports. 2024; 18: 17–23.

[18] Hu Q, Cheng S, Yuan C, Jin C. Recent research advances in imaging of prostate cancer. Journal of Biosciences and Medicines. 2024; 12: 114–128.

[19] Cohen D, Hazut Krauthammer S, Fahoum I, Kesler M, Even-Sapir E. PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies. European Radiology. 2023; 33: 6502–6512.

[20] Dondi F, Antonelli A, Suardi N, Guerini AE, Albano D, Lucchini S, et al. PET/CT and conventional imaging for the assessment of neuroendocrine prostate cancer: a systematic review. Cancers. 2023; 15: 4404.

[21] Li Y, Gao X, Yang J, Tang Y, Hu S. PSMA-negative widespread metastases identified by ¹⁸F-FDG PET/CT in treatment-related neuroendocrine prostate cancer with squamous differentiation. Clinical Nuclear Medicine. 2026; 51: 70–72.

[22] Al-Ibraheem A, Al-Adhami DA, Abdlkadir AS, Al-Hajaj N, Ghanem R, Abu-Hijlih R, et al. Molecular imaging in recurrent prostate cancer presented as a mixed small neuroendocrine tumor/acinar adenocarcinoma. Nuclear Medicine and Molecular Imaging. 2023; 57: 209–211.

[23] Sabater A, Sanchis P, Seniuk R, Pascual G, Anselmino N, Alonso DF, et al. Unmasking neuroendocrine prostate cancer with a machine learning-driven seven-gene stemness signature that predicts progression. International Journal of Molecular Sciences. 2024; 25: 11356.

[24] Hoshino Y, Kanao K, Miyama Y, Kosaka T, Kaneko G, Shirotake S, et al. Aggressive variant prostate cancer with multiple subcutaneous metastases: a case report. International Cancer Conference Journal. 2024; 13: 250–255.

[25] Zhu J, Liang X, Wu D, Chen S, Yang B, Mao W, et al. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: a population-based study. Medicine. 2021; 100: e25237.

[26] Ikeda J, Taniguchi H, Takayama H, Masuo Y, Nakamoto T, Uchida K, et al. A case of mixed neuroendocrine carcinoma-acinar adenocarcinoma: utilization of triplet therapy for prostate cancer. IJU Case Reports. 2024; 7: 459–462.

[27] Yao J, Liu Y, Liang X, Shao J, Zhang Y, Yang J, et al. Neuroendocrine carcinoma as an independent prognostic factor for patients with prostate cancer: a population-based study. Frontiers in Endocrinology. 2021; 12: 778758.

[28] Ullah A, Yasinzai AQK, Lee KT, Chaudhury T, Chaudhury H, Chandasir A, et al. Prognostic nomogram predicting survival and propensity score matching with demographics and comparative analysis of prostate small cell and large cell neuroendocrine carcinoma. Journal of Clinical Medicine. 2024; 13: 4874.

[29] Gu Y, Ly A, Rodriguez S, Zhang H, Kim J, Mao Z, et al. PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers. Cell Reports Medicine. 2024; 5: 101824.

[30] Tendler S, De Gregorio R, Balderes P, Michel AL, Hoang TT, Bauer D, et al. Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers. Proceedings of the National Academy of Sciences of the United States of America. 2026; 123: e2505785123.

[31] Zhu X, Ding CC, Aggarwal RR. Emerging therapeutic targets of neuroendocrine prostate cancer. Current Oncology Reports. 2025; 27: 362–374.